Simon has over six years of professional trading experience across FX, commodities and equities. He has a strong passion for financial markets and is particularly focused on price action trading
Shares of Open Orphan PLC (LON: ORPH) today extended yesterday’s decline despite announcing that its Venn Life Sciences division had secured a major contract renewal.
The rare and orphan drug consulting company yesterday reported that one of the top three global pharmaceutical companies had renewed its contract with the Venn Life Sciences division for the entire year.
The news triggered a brief rally in Open Orphan’s share price, which was soon followed by a pullback that saw the stock lose all its original gains and end the day lower.
Open Orphan’s team based in Breda, Netherlands, will fulfil the contract by providing chemistry, manufacturing and control consultancy (CMC) services to one of the client's vaccine development programmes.
Chairman Cathal Friel said: “We are delighted to enter 2021 with another contract signed by the Venn team in Breda with this top-three global pharmaceutical client.”
“Venn have been providing CMC support to this top tier company since 2012 and are pleased to be continuing to work with this client in their vaccine development programme.”
This is the second contract extension won by the Venn Life Sciences division given that the company made a similar announcement in late December.
Open Orphan share price
Today's open Orphan shares fell 2.98% to trade at 26.0p having fallen from yesterday’s closing price of 26.8p.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .